恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

休市中 12-19 16:08:06

70.750

+0.050

+0.07%

最高72.850	最低70.700	成交量1,138万
今开71.500	昨收70.700	日振幅3.04%
总市值4,696亿	流通市值182.54亿	总股本66.37亿
成交额8.09亿	换手率4.41%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":70.75,"timestamp":1766131686004,"preClose":70.7,"halted":0,"volume":11375474,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.1066540086686536,"marketStatus":"休市中","change":0.05,"latestTime":"12-19 16:08:06","open":71.5,"high":72.85,"low":70.7,"amount":809147126,"amplitude":0.03041,"askPrice":71,"askSize":3400,"bidPrice":70.75,"bidSize":11400,"shortable":3,"etf":0,"ttmEps":1.2839488340894412,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":70.7,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":4.15492676336662,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":60.85,"timestamp":1766127600000,"preClose":60,"halted":0,"volume":28835800,"delay":0,"premium":"+5.06"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2592157528","title":"恒瑞医药：SHR-9539注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157528","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592157528?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:11","pubTimestamp":1766135494,"startTime":"0","endTime":"0","summary":"南财智讯12月19日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司研发的SHR-9539注射液开展临床试验。审批结论显示，同意开展SHR-9539联合治疗在多发性骨髓瘤中的IB/II期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596828474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","BK0239","LU0405327494.USD","01276","LU1146622755.USD","LU2580892789.USD","LU2148510915.USD","LU2328871848.SGD","LU1781817850.SGD","LU2580892862.HKD","BK0012","BK0188","600276","LU1064130708.USD","LU1655091616.SGD","LU1969619763.USD","LU0359201612.USD","LU1580142542.USD","LU0405327148.USD","BK0196","LU1997244956.HKD","LU1064131003.USD","LU0359201885.HKD","LU2097828557.USD","LU1255011170.USD","LU1997245177.USD","LU2097828714.EUR","LU2097828474.EUR","LU2488822045.USD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","LU2097828631.EUR","BK0060","LU2289578879.USD","LU2097828805.USD","LU1820825898.SGD","BK0183","BK1191","LU1328615791.USD","BK0028","LU2495084118.USD"],"gpt_icon":0},{"id":"2592905538","title":"恒瑞医药12月18日遭主力抛售532.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592905538?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:15","pubTimestamp":1766045745,"startTime":"0","endTime":"0","summary":"12月18日, 恒瑞医药股价跌0.84%，报收70.70元，成交金额1.1亿元，换手率0.61%，振幅2.66%，量比0.53。恒瑞医药今日主力资金净流出532.7万元，上一交易日主力净流出430.9万元。|12月18日主力加仓幅度排名||#|股票简称|主力净额占比|#|汇舸环保|1.86%|#|香江电器|1.25%|#|中国科创产业投资|0.96%|#|...|...|#2570|恒瑞医药|-0.03%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162020a6b1a188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162020a6b1a188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","BK1191"],"gpt_icon":0},{"id":"2592973957","title":"诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973957","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973957?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027230,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。诺和诺德在美国的“高增长”依赖的是Wegovy的爆发式放量，而非整体产品线扩张。诺和诺德虽凭Wegovy实现高增长，却因技术代差、市场饱和与研发滞后被迫战略收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","01801","HK0000165453.HKD","01276","LU1969619763.USD","BK1583","BK1161","LU0455707207.USD","03933","BK1589","02196","LU2097828631.EUR","LU2097828557.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2242644610.SGD"],"gpt_icon":0},{"id":"2592490556","title":"医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490556","media":"交银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592490556?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:00","pubTimestamp":1765987200,"startTime":"0","endTime":"0","summary":"本周内资主要加仓龙头创新药企，包括恒瑞医药、荣昌生物和映恩生物；亦布局潜在受益于下游复苏的龙头CXO 企业，增持昭衍新药、晶泰控股和药明合联。投资启示：本周多项超10 亿美元的BD 交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，我们继续看好新BD 交易集中落地机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU0359202008.SGD","01276","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD","BK1191","02192","06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2592945829","title":"恒瑞医药“双艾”组合一线治疗不可切除肝癌最终分析结果见刊《柳叶刀·肿瘤学》","url":"https://stock-news.laohu8.com/highlight/detail?id=2592945829","media":"恒瑞医药","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592945829?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:03","pubTimestamp":1765962183,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药自主研发的创新药卡瑞利珠单抗联合阿帕替尼用于一线治疗不可切除肝细胞癌的全球多中心Ⅲ期CARES-310研究最终分析结果发表于《柳叶刀·肿瘤学》1。OS曲线图及亚组分析结果详见下图。延长随访进一步证实了卡瑞利珠单抗联合阿帕替尼良好的获益-风险特征，支持该联合方案作为不可切除或转移性肝细胞癌的一线治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217171808a4564540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217171808a4564540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU0359202008.SGD","LU0359201885.HKD","LU1023057109.AUD","01276","LU2543165471.USD"],"gpt_icon":1},{"id":"2592994588","title":"每日卖空追踪 | 恒瑞医药 12月17日卖空量成交2.84万股，卖空比例为2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994588","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592994588?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960219,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间12月17日，涨0.64%，卖空量成交2.84万股，较上一交易日减少93.39%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163247a6ad2398&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163247a6ad2398&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU2543165471.USD","LU0359201612.USD","LU0359202008.SGD","LU0359201885.HKD","LU1023057109.AUD","BK1191"],"gpt_icon":0},{"id":"2592799430","title":"12股获杠杆资金净买入超亿元，中国平安净买入居首","url":"https://stock-news.laohu8.com/highlight/detail?id=2592799430","media":"E公司","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592799430?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:04","pubTimestamp":1765937049,"startTime":"0","endTime":"0","summary":"人民财讯12月17日电，截至12月16日，市场融资余额合计2.49万亿元，较前一交易日减少4.59亿元。具体到个股，12月16日获融资净买入千万元以上的有354只，其中12只融资净买入额超亿元。中国平安融资净买入额居首，当日净买入7.54亿元，其次是永辉超市、航天电子，融资净买入金额分别为4.26亿元、2.19亿元，融资净买入金额居前的还有恒瑞医药、北汽蓝谷、特变电工等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217100409a6abc096&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217100409a6abc096&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BVYPNQ40.USD","LU0348783662.USD","LU0417516571.SGD","LU0348814723.USD","PNGAY","LU1282648689.USD","LU0043850808.USD","LU0588545490.SGD","LU1719994722.HKD","LU0197773160.USD","LU1282649141.HKD","LU0651947912.USD","LU0084288322.USD","LU1235295612.USD","LU0327786744.USD","LU0049112450.USD","LU0588545904.SGD","LU0594300179.USD","LU0164872284.USD","LU1044874839.SGD","LU0359202008.SGD","LU2399975544.HKD","LU0051755006.USD","LU1981816686.USD","LU1048588211.SGD","BK1507","LU1993786604.SGD","LU0039217434.USD","HPAD.SI","02318","LU0918141705.HKD","03145","LU0417516902.SGD","IE00BMCWC346.EUR","LU1831875114.USD","LU1961090484.USD","BK1191","LU0197773673.USD","LU0762541174.USD","LU0348783233.USD","601318","LU0244354667.USD","LU0149721374.USD","PAImain","01276","LU0588546209.SGD","LU2226246903.HKD","82318","LU0314109678.HKD"],"gpt_icon":0},{"id":"2592943229","title":"中国创新药领域已构成“黄金三角”，行业发展迎来强劲动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943229","media":"制药网","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592943229?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:46","pubTimestamp":1765935968,"startTime":"0","endTime":"0","summary":"当前中国创新药产业正迎来历史性突破。而这一跨越的背后，业内指出，是研发投入做“加法”、审评审批流程做“减法”、市场空间做“乘法”构成的“黄金三角”正向循环，为创新药发展注入了强劲动能。此外，2025年至今，国内已批准上市的创新药达到69个，再创新高。其中，12月7日，国家医保局正式发布2025年国家医保目录和首版商保创新药目录，新增了114种药品纳入医保报销范围，包含50种1类创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359201885.HKD","BK1191","LU2543165471.USD","LU1023057109.AUD","LU0359201612.USD","BK1161","LU0359202008.SGD","02615","01276","06978"],"gpt_icon":0},{"id":"2592349994","title":"Tides 速递 | 恒瑞医药：Kailera启动GLP-1/GIP三项全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2592349994","media":"多肽圈","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592349994?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:19","pubTimestamp":1765934385,"startTime":"0","endTime":"0","summary":"GLP-1/GIP双靶点激动剂HRS-9531于今年9月国内上市申请获得受理，此次则启动全球三期临床。后续还有小分子GLP-1受体激动剂HRS-7535、HRS-9531的口服版本，此外GLP-1/GIP/GCG三靶点激动剂HRS-4729处于一期临床阶段。首付款加潜在里程碑付款累计可高达60亿美元，公司还取得Kailera19.9%的股权。Kailera正在全球推进HRS9531的临床开发，代号为KAI-9531。目前该药物的全球Ⅲ期临床项目预计于年底前启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094109a6aba68e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094109a6aba68e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1191","LU0359201885.HKD","01276","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD"],"gpt_icon":1},{"id":"2591022646","title":"东方财富证券：创新浪潮涌动下 关注医药板块修复与突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022646?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:25","pubTimestamp":1765873557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为未来License-out项目的重点方向。东方财富证券主要观点如下：今年以来，在创新药、AI医疗的带动下，化学制药板块领涨医药板块估值水平接近最近10年历史平均水平。中国创新药十年变革主要得益于全面的监管改革、研发投入的增加以及战略性的全球化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","01276","300059","HK0000165453.HKD","LU1969619763.USD","LU1997245177.USD","159938","LU1831875114.USD","BK0196","LU2543165471.USD","LU0588546209.SGD","LU2097828474.EUR","LU2097828631.EUR","IE00BZ08YT58.USD","LU0359202008.SGD","LU2580892789.USD","BK0028","06160","LU1997244956.HKD","LU2097828557.USD","LU1770034418.SGD","LU2097828714.EUR","LU2495084118.USD","LU2097828805.USD","LU0307460666.USD","LU1064131003.USD","BK1521","LU1303224171.USD","BK0077","BK1500","BK1583","161027","SG9999014674.SGD","IE00BZ08YR35.GBP","BK1589","LU0326950275.SGD","LU1719994722.HKD","01177","BK1574","LU2289578879.USD","LU2328871848.SGD","09939","IE00BZ08YS42.EUR","LU2148510915.USD","BK0095","BK0188","BK1588","LU1251922891.USD"],"gpt_icon":0},{"id":"2591935320","title":"深度研究报告|创新药出海潮起：恒瑞医药、百济神州领航","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935320","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935320?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:21","pubTimestamp":1765862507,"startTime":"0","endTime":"0","summary":"▲ 定档2026年5月29-30日苏州！精益智造·链接全球：2026中国制药产业大会重磅官宣！●如需获取完整版报告，关注“药视声”并回复“出海”，即可获得！文章来源：东吴证券研究所","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU2328871848.SGD","LU0307460666.USD","BK1191","BK1161","06978","LU1969619763.USD","LU0359201885.HKD","LU1770034418.SGD","06160","01276","LU0359202008.SGD","LU1303224171.USD","BK1583","LU1719994722.HKD","BK1588","LU2543165471.USD","BK1574","LU1023057109.AUD","LU0359201612.USD","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2591264877","title":"小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264877","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264877?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:59","pubTimestamp":1765796342,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0820561818.USD","LU0170899867.USD","LU2552382058.USD","LU0942090050.USD","BK0012","IE00BJTD4N35.SGD","LU2552382215.SGD","IE00BKVL7J92.USD","BK4588","LU2417539215.USD","LU1116320737.USD","LU0267386448.USD","LU0048584097.USD","LU2237443895.HKD","LU1146622755.USD","LU0211328371.USD","LU0211326755.USD","LU0496365809.HKD","LU2462157665.USD","LU0359202008.SGD","LU1997244956.HKD","LU1997245177.USD","BK4504","600276","LU1551013342.USD","LU1551013425.SGD","BK4207","LU1988902786.USD","LU2456880835.USD","LU1244550494.USD","IE00BN8TJ469.HKD","IE00BJLML261.HKD","LU1064130708.USD","LU2756315664.SGD","LU0964807845.USD","BK4585","LU0345769128.USD","LU1366192091.USD","LU2097828805.USD","LU2213496289.HKD","01276","BK4550","BK4566","LU2592432038.USD","LU0405327494.USD","LU0868494617.USD","LU2495084118.USD","IE00BKDWB100.SGD","LU0405327148.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2591453816","title":"每日卖空追踪 | 恒瑞医药 12月15日卖空量成交8.22万股，卖空比例为2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591453816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591453816?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787419,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间12月15日，跌0.14%，卖空量成交8.22万股，较上一交易日减少88.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163258a6a455c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163258a6a455c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","LU1023057109.AUD","LU0359202008.SGD","BK1191","01276"],"gpt_icon":0},{"id":"2591645352","title":"恒瑞医药12月15日遭主力抛售649.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645352","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591645352?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:16","pubTimestamp":1765786564,"startTime":"0","endTime":"0","summary":"12月15日, 恒瑞医药股价跌0.14%，报收72.35元，成交金额2.0亿元，换手率1.09%，振幅3.66%，量比0.78。恒瑞医药今日主力资金净流出649.6万元，连续3日净流出，上一交易日主力净流出1605.4万元。该股近5个交易日上涨0.55%，主力资金累计净流出1722.7万元；近20日主力资金累计净流入1.2亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215162256a44d32d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215162256a44d32d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","BK1191","01276","LU0359201612.USD"],"gpt_icon":0},{"id":"2591616750","title":"智通AH统计|12月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616750?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月15日收盘，东北电气、京城机电股份、弘业期货分列AH溢价率前三位，溢价率分别为900.00%、266.67%、265.78%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.03%、-0.77%、1.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00317","00042","03968","02218","BK1594","02865","LU0244354667.USD","01276","06818","01057","BK1565","03750","LU1522347837.USD","02238","03143","02338","01618","01033","LU0348827113.USD","BK1562","00548","01812","01349","02359","03606","159982","00177","00638","LU1105468828.SGD","00300","01528","399300","01339","LU0823426480.USD","00187","00916","06826","00038","LU0886674414.USD","06127","01988","00553","02899","03678","01108","IE00B29SXG58.USD","LU1504937902.USD"],"gpt_icon":1},{"id":"2591960609","title":"12月以来，药明巨诺、恒瑞医药、南新制药等大批药企高管变动！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591960609","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591960609?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:54","pubTimestamp":1765785283,"startTime":"0","endTime":"0","summary":"年末，国内医药行业高管变动进入密集期。根据梳理，近期，多家药企发布高管变动公告，涉及药明巨诺、恒瑞医药、南新制药、康恩贝等。12月10日，南新制药发布公告，宣布原非独立董事彭程因个人原因辞去相关职务，副总经理兼财务总监李亮因工作调整辞任。除了以上企业，12月以来，百奥赛图、维康药业、复锐医疗也有高管因个人原因、工作调动等原因辞任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216085448a6a70ec0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216085448a6a70ec0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359201885.HKD","LU2543165471.USD","BK1191","LU0359202008.SGD","01276","LU0359201612.USD","BK1583","LU1023057109.AUD","BK1161","02126"],"gpt_icon":0},{"id":"2591970396","title":"恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》","url":"https://stock-news.laohu8.com/highlight/detail?id=2591970396","media":"新浪科技","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591970396?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:59","pubTimestamp":1765778340,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》 ，这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。　　“FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","LU2580892862.HKD","LU2495084118.USD","BK0196","LU1023057109.AUD","LU1064130708.USD","LU2097828557.USD","BK0028","LU1255011170.USD","LU2543165471.USD","LU1146622755.USD","LU1580142542.USD","BK0183","LU1997244956.HKD","600276","LU1328615791.USD","LU2097828714.EUR","LU1997245094.SGD","CA","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","LU0359201885.HKD","LU2097828631.EUR","BK0012","LU0405327148.USD","BK0060","01276","BK0239","BK0188","LU2328871848.SGD","LU2580892789.USD","LU0359201612.USD","BK1191","LU2097828474.EUR","LU0359202008.SGD","LU1820825898.SGD","LU1655091616.SGD","LU0405327494.USD","LU2289578879.USD","LU2097828805.USD"],"gpt_icon":1},{"id":"2591699288","title":"国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591699288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591699288?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:41","pubTimestamp":1765766465,"startTime":"0","endTime":"0","summary":"建议关注恒瑞医药：FXI单抗SHR-2004进入3期临床，在国产分子中领先;并关注拥有FXI小核酸药物管线的公司。国信证券主要观点如下：FXI/FXIa抑制剂有望成为安全性更优的抗凝药物现有抗凝血药物均作用于凝血的共同通路，FXI仅参与内源性凝血通路以及血栓的正反馈放大，抑制FXI活性有望在抗凝血的同时减少出血的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","01276","BK0183","LU2097828474.EUR","LU1328615791.USD","BK1191","LU1997245094.SGD","LU2097828557.USD","LU2148510915.USD","LU2495084118.USD","LU2097828805.USD","LU0359201885.HKD","LU1997245177.USD","LU0405327148.USD","LU1064131003.USD","LU2289578879.USD","LU2543165471.USD","LU1023057109.AUD","BK0012","LU2097828714.EUR","BK0196","LU1146622755.USD","BK0028","LU1969619763.USD","LU1997244956.HKD","600276","LU2488822045.USD","BK0276","LU0359201612.USD","002736","BK0060","LU1820825898.SGD","LU0405327494.USD","LU2580892789.USD","BK0188","LU1781817850.SGD","LU2580892862.HKD","LU1064130708.USD","LU1255011170.USD","BK0239","LU1655091616.SGD","LU1580142542.USD","LU2097828631.EUR","LU0359202008.SGD"],"gpt_icon":0},{"id":"2591660538","title":"国产创新药迎利好密集期！九安医疗产品获FDA批准，一品红斩获近70亿元大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591660538","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591660538?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:27","pubTimestamp":1765754852,"startTime":"0","endTime":"0","summary":"九安医疗公告，公司美国子公司四联检、三联检产品获得美国FDA上市前通知，涉及的产品包括甲型流感、乙型流感、COVID-19及RSV呼吸道合胞病毒四联检测家用试剂盒等。一品红公告，芩香清解口服液获批国家中药二级保护品种。这些优势使中国药企在全球医药交易中的占比迅速提升，2025年成为中国创新药对外授权交易的爆发之年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0455707207.USD","HK0000165453.HKD","LU1969619763.USD","BK1161","LU2097828474.EUR","01801","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","BK1583","03692","BK1589","BK1574","LU2328871848.SGD","06978","01877","LU0502904849.HKD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2591663795","title":"周评 | 首批商保创新药目录出炉，只是万里长征的第一步！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663795","media":"中保新知","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663795?lang=zh_cn&edition=full","pubTime":"2025-12-14 19:28","pubTimestamp":1765711720,"startTime":"0","endTime":"0","summary":"近日，国家医保局正式发布首版《商业健康保险创新药品目录》，包括CAR-T等19种高价药品。硬币两面《目录》更重要的是明确了商保在多层次医疗保障体系中的地位和定位，此前惠民保等产品其实已经将CAR-T等动辄百万元的药品纳入保障范围，因此就高价药和创新药而言，《目录》并不是石破天惊的第一次。人们常用“最后一公里”来形容，其实更像是万里长征第一步之后的砥砺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214193959a449fe90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214193959a449fe90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0149721374.USD","LU2476274308.USD","LU0630378429.USD","LU0315179316.USD","02318","LU0588545490.SGD","LU1794554557.SGD","IE00BZ08YR35.GBP","LU0648948544.HKD","LU2348774022.SGD","LU0051755006.USD","LU0054450605.USD","01276","LU0878005551.USD","LU0594300179.USD","06978","IE0034224299.USD","LU0348788117.USD","BK1550","LU1366334578.USD","82318","LU0640798160.USD","LU0039217434.USD","601318","LU0348783233.USD","LU0348735423.USD","LU0823426308.USD","LU1366334651.USD","SG9999002463.SGD","IE00BMCWC346.EUR","LU0918141887.USD","LU0314109678.HKD","PAImain","LU0067412154.USD","LU2226246903.HKD","LU0348816934.USD","LU0880133367.SGD","HPAD.SI","LU0762541174.USD","LU0417516571.SGD","LU0196878994.USD","PNGAY","HK0000320264.USD","LU1048588211.SGD","03145","LU0630378692.HKD","LU0878004406.USD","IE00BGHQDM52.EUR","LU0828237940.HKD","IE0003895053.USD","LU1044876610.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0014},{"period":"3month","weight":-0.1924},{"period":"6month","weight":0.2567},{"period":"1year","weight":0.6061},{"period":"ytd","weight":0.6061}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}